LIVIVO - Search results -

Search results

Result 1 - 10 of total 27

Search options

Article: Mid-life extra-haematopoetic manifestations of Diamond-Blackfan anaemia.

Muir, Christopher / Dodds, Anthony / Samaras, Katherine

Endocrinology, diabetes & metabolism case reports

2017 Volume 2017

Abstract: Summary: Diamond-Blackfan anaemia (DBA) is a rare cause of bone marrow failure. The incidence of malignancy and endocrine complications are increased in DBA, relative to other inherited bone marrow failure syndromes. We describe an adult woman with DBA ... ...

Abstract	Summary: Diamond-Blackfan anaemia (DBA) is a rare cause of bone marrow failure. The incidence of malignancy and endocrine complications are increased in DBA, relative to other inherited bone marrow failure syndromes. We describe an adult woman with DBA who developed osteoporosis and avascular necrosis (AVN) of both distal femora. Such endocrine complications are not uncommon in DBA, but under-appreciated, especially in adulthood. Further, rectal adenocarcinoma was diagnosed at age 32 years, requiring hemi-colectomy and adjuvant chemotherapy. Elevated cancer risk may warrant disease-specific screening guidelines. Genetic predictors of extra-haematopoetic complications in DBA are yet to be established. Learning points: Endocrine complications are common in DBA.Clinical vigilance is required in managing bone health of DBA patients treated with glucocorticoids.There is currently no reliable way to predict which patients will develop complications of therapy or premature malignancy related to DBA.Complaints of bone or joint pain should prompt screening with targeted magnetic resonance imaging. Osteoporosis screening should be performed routinely.
Language	English
Publishing date	2017-04-19
Publishing country	England
Document type	Journal Article
ZDB-ID	2785530-2
ISSN	2052-0573
ISSN	2052-0573
DOI	10.1530/EDM-16-0141
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis.

Brennan, Xavier / Withers, Barbara / Jabbour, Andrew / Milliken, Sam / Kotlyar, Eugene / Fay, Keith / Ma, David / Muthiah, Kavitha / Hamad, Nada / Dodds, Anthony / Bart, Nikki / Keogh, Anne / Hayward, Chris / Macdonald, Peter / Moore, John

Internal medicine journal

2022 Volume 52, Issue 10, Page(s) 1826–1830

Abstract: Cardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late-stage cardiac AL ...

Abstract	Cardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late-stage cardiac AL amyloidosis. The primary end points were overall survival and haematological response. Both regimens provided meaningful responses in this difficult to treat patient group.
MeSH term(s)	Humans ; Bortezomib ; Immunoglobulin Light-chain Amyloidosis/drug therapy ; Melphalan ; Retrospective Studies ; Dexamethasone ; Amyloidosis/drug therapy ; Cyclophosphamide
Chemical Substances	Bortezomib (69G8BD63PP) ; Melphalan (Q41OR9510P) ; Dexamethasone (7S5I7G3JQL) ; Cyclophosphamide (8N3DW7272P)
Language	English
Publishing date	2022-10-28
Publishing country	Australia
Document type	Journal Article
ZDB-ID	2045436-3
ISSN	1445-5994 ; 1444-0903
ISSN (online)	1445-5994
ISSN	1444-0903
DOI	10.1111/imj.15926
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 792: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 424: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effect of donor age on adult unrelated donor haemopoietic cell transplant outcome: the Australian experience.

Nivison-Smith, Ian / Bajel, Ashish / Dodds, Anthony J / Gottlieb, David / Hamad, Nada / Kennedy, Glen / Kerridge, Ian / Ma, David D F / Milliken, Samuel / Moore, John / Purtill, Duncan / Szer, Jeff

Internal medicine journal

2020 Volume 52, Issue 1, Page(s) 57–62

Abstract: Background: Results have been varied regarding the effect of donor age on the outcome of unrelated donor haemopoietic cell transplantation (HCT).: Aims: To determine the influence of donor age on adult unrelated donor HCT outcome in Australia.: ... ...

Abstract	Background: Results have been varied regarding the effect of donor age on the outcome of unrelated donor haemopoietic cell transplantation (HCT). Aims: To determine the influence of donor age on adult unrelated donor HCT outcome in Australia. Methods: Patients were included in the study if they were aged 16 years or above and underwent first allogeneic unrelated donor HCT in Australia for the indications of acute lymphoblastic leukaemia (ALL), acute myelogenous leukaemia (AML), chronic myelogenous leukaemia (CML) or myelodysplastic syndromes (MDS) between the years of 2001 and 2014 inclusive. The main outcome measure was overall survival (OS), which was tested against independent variables using univariate Kaplan-Meier methods and multivariate Cox regression. Results: A total of 1158 unrelated donor HCT were represented in the data. Cumulative incidences of engraftment, transplant related mortality (TRM), acute graft-versus-host disease (GvHD), chronic GvHD and relapse were not significantly affected by donor age. OS probability at 5 years post-transplant was 48.3%. In multivariate analysis of OS, year of transplant 2001-2007, recipient age 40 years or greater, poor risk disease, human leukocyte antigen (HLA) match less than 6/6 and poor performance status at transplant (Karnofsky scale) were independently significant adverse OS risk factors. Donor age was not a significant risk factor for OS in univariate or multivariate analysis. Conclusions: The conclusion from this study was that donor age (up to 59 years) did not influence post-transplant outcome among adult unrelated donor HCT performed in Australia for haematologic malignancies.
MeSH term(s)	Adolescent ; Adult ; Australia/epidemiology ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Neoplasm Recurrence, Local ; Treatment Outcome ; Unrelated Donors
Language	English
Publishing date	2020-11-02
Publishing country	Australia
Document type	Journal Article
ZDB-ID	2045436-3
ISSN	1445-5994 ; 1444-0903
ISSN (online)	1445-5994
ISSN	1444-0903
DOI	10.1111/imj.15128
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 792: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 424: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Trends in disease indications for hematopoietic stem cell transplantation in the Asia-Pacific region: A report of the Activity Survey 2017 from APBMT.

Iida, Minako / Liu, Kaiyan / Huang, Xiao Jun / Depei, Wu / Kuwatsuka, Yachiyo / Moon, Joon Ho / Dodds, Anthony / Wilcox, Leonie / Ko, Bor-Sheng / Hamidieh, Amir Ali / Ho, Kim Wah / Ungkanont, Artit / Ho, Aloysius / Farzana, Tasneem / Sim, Joycelyn / Man, Huynh Van / Akter, Mafruha / Abeysinghe, Prasad / Bravo, Marjorie Rose /

Gyi, Aye Aye / Poudyal, Bishesh Sharma / Batshkh, Khishigjargal / Srivastava, Alok / Okamoto, Shinichiro / Atsuta, Yoshiko

Blood cell therapy

2022 Volume 5, Issue 4, Page(s) 87–98

Abstract: The Asia-Pacific Blood and Marrow Transplantation Group (APBMT) has been conducting annual surveys on the activity of hematopoietic stem cell transplants since 2007. The APBMT Data Center collected the following data in 2017. A total of 21,504 ... ...

Abstract	The Asia-Pacific Blood and Marrow Transplantation Group (APBMT) has been conducting annual surveys on the activity of hematopoietic stem cell transplants since 2007. The APBMT Data Center collected the following data in 2017. A total of 21,504 transplants were registered from 733 transplant centers of 20 countries/regions in the Asia-Pacific (AP) region. Five countries/regions comprised 89.4% of all transplants - China (6,979), Japan (5,794), South Korea (2,626), India (2,034), and Australia (1,789). The number of centers in these five countries/regions also comprised 88.9% of all centers: Japan (373), China (123), India (66), Australia (45), and South Korea (44). The overall ratio between autologous and allogeneic transplants was 37.0% and 63.0%, respectively, but the ratios varied significantly among countries/regions. Autologous transplants have surpassed allogeneic transplants in Thailand, Australia, Vietnam, New Zealand, Singapore, and Iran. In contrast, the proportion of allogeneic transplants comprised over 70% of all transplants in Pakistan, China, and Hong Kong. These ratios were compared by the Data Center among countries/regions that performed more than 50 transplants. The proportion of related and unrelated transplants also differed among countries/regions. The number of unrelated transplants was more than related ones in Japan (2,551 vs. 1,202) and Australia (329 vs. 291), whereas more than 80% of all transplants were related transplants in Malaysia (90.9%), India (89.5%), Iran (87.2%), Vietnam (85.7%), China (80.9%), and Thailand (80.6%). All transplant activities were related transplants in Pakistan, the Philippines, Myanmar, and Nepal, and no allogeneic transplants were performed in Bangladesh and Mongolia. Regarding the indications for transplants, acute myeloid leukemia (AML) was the most common disease for allogeneic transplant (4,759, 35.1% of allogeneic transplants), while plasma cell disorder (PCD) was the most common disease for autologous transplant (3,701, 27.3% of all autologous transplants). Furthermore, the number of transplants for hemoglobinopathy has steeply increased in this region compared with the rest of disease indications (677, 3.1% of all transplants). APBMT covers a broad area globally, including countries/regions with diverse disease distribution, development of HSCT programs, population, and economic power. Consistent and continuous activity surveys considering those elements in each country/region revealed the HSCT field's diverse characteristics and background factors in this region.
Language	English
Publishing date	2022-07-08
Publishing country	Japan
Document type	Journal Article
ISSN	2432-7026
ISSN (online)	2432-7026
DOI	10.31547/bct-2022-002
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Report on hematopoietic cell transplantations performed in 2018/2019 focusing on the trends of selection of stem cell sources in the Asia-Pacific region: APBMT Activity Survey.

Iida, Minako / Liu, Kaiyan / Huang, Xiao Jun / Huang, He / Kuwatsuka, Yachiyo / Moon, Joon Ho / Lee, Jong Wook / Lakshmi, Kavitha M / Dodds, Anthony / Wilcox, Leonie / Ko, Bor-Sheng / Hamidieh, Amir Ali / Behfar, Maryam / Ho, Kim Wah / Bunworasate, Udomsak / Ho, Aloysius / Farzana, Tasneem / Sim, Joycelyn / Dung, Phu Chi /

Akter, Mafruha / Ratnayake, Wasantha / Bravo, Marjorie Rose / Gyi, Aye Aye / Santosa, Damai / Poudyal, Bishesh Sharma / Batshkh, Khishigjargal / Srivastava, Alok / Okamoto, Shinichiro / Atsuta, Yoshiko

Blood cell therapy

2023 Volume 6, Issue 4, Page(s) 114–123

Abstract: The number of hematopoietic stem cell transplantations (HCTs) is increasing annually worldwide, and the Asia-Pacific (AP) region is no exception. We report on the absolute number of HCTs in 2018 and 2019 and the trends in graft selection and disease ... ...

Abstract	The number of hematopoietic stem cell transplantations (HCTs) is increasing annually worldwide, and the Asia-Pacific (AP) region is no exception. We report on the absolute number of HCTs in 2018 and 2019 and the trends in graft selection and disease indication in the past few decades. In 2018, 24,292 HCTs were performed in the AP region, of which 8,754 (36.0%) were autologous and 15,538 (64.0%) were allogeneic. Among the allogeneic HCTs, 10,552 (67.9%) of the recipients were related to their donors, whereas 4,986 (32.1%) were unrelated. In 2019, 27,583 HCTs were reported, of which 17,613 (63.9%) were allogeneic and 9,970 (36.1%) were autologous. Although, in 2010, there was a nearly equal number of related and unrelated HCTs, the difference has shown an annual increase, with more than double (2.05) the number of related than unrelated HCTs in 2019. Recent trends in the AP region show that peripheral blood has overwhelmingly surpassed the bone marrow as a graft source for both related and unrelated HCTs, with the haploidentical donor type being preferred; however, their trends in each country/region were quite different among countries/regions. In 2019, the main conditions requiring HCT were acute myelogenous leukemia (n=6,629 [24.0%]), plasma cell disorders (PCD) (n=4,935 [17.9%]), malignant lymphoma (ML) (n=4,106 [14.9%]), acute lymphoblastic leukemia (AML) (n=3,777 [13.7%]), myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm (n=1,913 [6.9%]), severe aplastic anemia (n=1,671 [6.1%]), and hemoglobinopathy (n=910 [3.3%]). PCD and ML were the main indications for autologous HCT, and the number of PCD cases has grown more prominent than the corresponding of ML. The increased number of allogeneic transplants for hemoglobinopathy remains prominent, as well as that of AML and acute lymphocytic leukemia for the past 5 years. There was a significant regional variation in the number of facilities performing HCTs, ranging from one in Mongolia and Nepal to 313 in Japan, and differing regional densities varying from 0.1 in Indonesia and Pakistan to 24.7 in Japan. The total transplant density per 10 million population in each country/region also differed (0.2 in Indonesia and 627 in New Zealand). This annual Activity Survey aims to help all participating countries/regions understand the changes in HCT, serve as an asset in promoting HCT activities in the AP region, and be used as a reference for comparison with other registries from Europe and the United States.
Language	English
Publishing date	2023-10-06
Publishing country	Japan
Document type	Journal Article
ISSN	2432-7026
ISSN (online)	2432-7026
DOI	10.31547/bct-2023-015
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: A Review of Hematopoietic Cell Transplantation in Australia and New Zealand, 2005 to 2013.

Nivison-Smith, Ian / Bardy, Peter / Dodds, Anthony J / Ma, David D F / Aarons, Donna / Tran, Steven / Wilcox, Leonie / Szer, Jeff

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

2016 Volume 22, Issue 2, Page(s) 284–291

Abstract: This report describes hematopoietic cell transplantation (HCT) activity and outcome in Australia and New Zealand during the years 2005 to 2013. In 2013, 1018 autologous, 221 allogeneic with related donors, and 264 allogeneic with unrelated donors HCT ... ...

Abstract	This report describes hematopoietic cell transplantation (HCT) activity and outcome in Australia and New Zealand during the years 2005 to 2013. In 2013, 1018 autologous, 221 allogeneic with related donors, and 264 allogeneic with unrelated donors HCT were performed in 40 centers in Australia, with corresponding figures of 147, 39, and 47 in 6 centers in New Zealand. Annual numbers of HCT in 2013 increased, compared to 2005, by 25% in Australia and by 52% in New Zealand. The majority of both allogeneic and autologous HCT used peripheral blood as the stem cell source for all years studied. Major indications for transplantation were acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), plasma cell disorders, and non-Hodgkin lymphoma (NHL). Overall survival probabilities at 5 years after transplantation for adult (16+) allogeneic first HCT recipients were 54.2% for ALL, 46.0% for AML, 48.4% for myelodysplastic syndromes, and 58.6% for NHL. Consistent patterns over time include a steady increase in HCT, particularly for older recipients, relatively constant numbers of allografts using cord blood, and a recent increase in the number of allografts with 2 or more HLA-mismatched related donors.
MeSH term(s)	Adolescent ; Adult ; Aged ; Australia ; Child ; Child, Preschool ; Hematopoietic Stem Cell Transplantation/methods ; Hematopoietic Stem Cell Transplantation/mortality ; History, 21st Century ; Humans ; Infant ; Middle Aged ; New Zealand ; Transplantation Conditioning/methods ; Transplantation Conditioning/mortality ; Young Adult
Language	English
Publishing date	2016-02
Publishing country	United States
Document type	Historical Article ; Journal Article ; Review
ZDB-ID	1474865-4
ISSN	1523-6536 ; 1083-8791
ISSN (online)	1523-6536
ISSN	1083-8791
DOI	10.1016/j.bbmt.2015.09.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5082: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 462: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The 2016 APBMT Activity Survey Report: Trends in haploidentical and cord blood transplantation in the Asia-Pacific region.

Blood cell therapy

2021 Volume 4, Issue 2, Page(s) 20–28

Abstract: This report describes the results of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT) Activity Survey 2016, focusing on the trends of haploidentical and cord blood (CB) transplants in the Asia-Pacific region. Mongolia and Nepal submitted ... ...

Abstract	This report describes the results of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT) Activity Survey 2016, focusing on the trends of haploidentical and cord blood (CB) transplants in the Asia-Pacific region. Mongolia and Nepal submitted their first activity data in this survey, and the number of countries/regions participating in the activity survey grew to 20. The annual number of transplants exceeded 20,000 for the first time in 2016, and the total number of centers increased to 686. About 87.9% of all hematopoietic stem cell transplantations (HSCTs) were performed in China, Japan, Korea, India, and Australia with China performing the highest number. Beginning with the 2016 survey, APBMT modified the survey forms and initiated the collection of the exact number of haploidentical transplants. The total number of such transplants was 3,871, and 66.0% of those were performed in China. Meanwhile, cord blood transplants in this region remained high (1,612), and 81.8% of them (1,319) were performed in Japan. The number of facilities and transplants, the ratio of haploidentical transplants to related transplants, the ratio of CB transplants to unrelated transplants, and proportions of haploidentical and CB transplants per capita significantly differed among countries/regions in the Asia-Pacific region. Data collection and analysis revealed the transition and diversity of transplants in this region. This report also shows a dramatic increase in haploidentical transplants as seen in other parts of the world, while revealing uniquely that the activity of cord blood transplant remains high in this region.
Language	English
Publishing date	2021-01-29
Publishing country	Japan
Document type	Journal Article
ISSN	2432-7026
ISSN (online)	2432-7026
DOI	10.31547/bct-2020-013
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis.

Ma, Chun Kei Kris / García-Cadenas, Irene / Fox, María Laura / Ai, Sylvia / Nivison-Smith, Ian / Milliken, Samuel Thomas / Dodds, Anthony / Fay, Keith / Ma, David D F / Martino, Rodrigo / Sierra, Jorge / Moore, John

Bone marrow transplantation

2018 Volume 53, Issue 11, Page(s) 1478–1482

MeSH term(s)	Acute Disease ; Etanercept/pharmacology ; Etanercept/therapeutic use ; Female ; Graft vs Host Disease/drug therapy ; Graft vs Host Disease/pathology ; Humans ; Immunosuppressive Agents/pharmacology ; Immunosuppressive Agents/therapeutic use ; Male ; Middle Aged ; Prognosis
Chemical Substances	Immunosuppressive Agents ; Etanercept (OP401G7OJC)
Language	English
Publishing date	2018-05-24
Publishing country	England
Document type	Letter ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-018-0215-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A population-based cohort study of late mortality in adult autologous hematopoietic stem cell transplant recipients in Australia.

Ashton, Lesley J / Le Marsney, Renate E / Dodds, Anthony J / Nivison-Smith, Ian / Wilcox, Leonie / O'Brien, Tracey A / Vajdic, Claire M

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

2014 Volume 20, Issue 7, Page(s) 937–945

Abstract: We assessed overall and cause-specific mortality and risk factors for late mortality in a nation-wide population-based cohort of 4547 adult cancer patients who survived 2 or more years after receiving an autologous hematopoietic stem cell transplantation ...

Abstract	We assessed overall and cause-specific mortality and risk factors for late mortality in a nation-wide population-based cohort of 4547 adult cancer patients who survived 2 or more years after receiving an autologous hematopoietic stem cell transplantation (HSCT) in Australia between 1992 and 2005. Deaths after HSCT were identified from the Australasian Bone Marrow Transplant Recipient Registry and through data linkage with the National Death Index. Overall, the survival probability was 56% at 10 years from HSCT, ranging from 34% for patients with multiple myeloma to 90% for patients with testicular cancer. Mortality rates moved closer to rates observed in the age- and sex-matched Australian general population over time but remained significantly increased 11 or more years from HSCT (standardized mortality ratio, 5.9). Although the proportion of deaths from nonrelapse causes increased over time, relapse remained the most frequent cause of death for all diagnoses, 10 or more years after autologous HSCT. Our findings show that prevention of disease recurrence remains 1 of the greatest challenges for autologous HSCT recipients, while the increasing rates of nonrelapse deaths due to the emergence of second cancers, circulatory diseases, and respiratory diseases highlight the long-term health issues faced by adult survivors of autologous HSCT.
MeSH term(s)	Adolescent ; Adult ; Aged ; Australia/epidemiology ; Cohort Studies ; Female ; Hematopoietic Stem Cell Transplantation/statistics & numerical data ; Humans ; Male ; Middle Aged ; Neoplasms/mortality ; Neoplasms/therapy ; Survival Analysis ; Transplantation, Autologous ; Young Adult
Language	English
Publishing date	2014-07
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1474865-4
ISSN	1523-6536 ; 1083-8791
ISSN (online)	1523-6536
ISSN	1083-8791
DOI	10.1016/j.bbmt.2014.03.006
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5082: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 462: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Incident cancers and late mortality in Australian children treated by allogeneic stem cell transplantation for non-malignant diseases.

Nelson, Adam S / Vajdic, Claire M / Ashton, Lesley J / Le Marsney, Renate E / Nivison-Smith, Ian / Wilcox, Leonie / Dodds, Anthony J / O'Brien, Tracey A

Pediatric blood & cancer

2017 Volume 64, Issue 1, Page(s) 197–202

Abstract: Background: Hematopoietic stem cell transplantation (HSCT) is a life-saving procedure for children with a variety of non-malignant conditions. However, these children face an increased risk of late death and incident cancers after HSCT, which may occur ... ...

Abstract	Background: Hematopoietic stem cell transplantation (HSCT) is a life-saving procedure for children with a variety of non-malignant conditions. However, these children face an increased risk of late death and incident cancers after HSCT, which may occur many years after their initial HSCT. Procedure: We examined cancer occurrence and late mortality in a population-based cohort of 318 Australian children who underwent allogeneic HSCT for non-malignant disease. Standardized incident ratios (SIRs) and standardized mortality ratios (SMRs) were calculated and compared with population controls. Results: We identified six (1.9%) cancers at a median 9.2 years post-HSCT. Cancer occurred 15 times more frequently than in the general population (SIR 15.4, 95% CI = 6.9-34.2). Of the 198 patients who survived for at least 2 years post-HSCT, 11 (5.6%) died at a median 7.5 years post-HSCT. The mortality rate was 17 times higher than in the general population (SMR 17.5, 95% CI = 9.7-31.2). Discussion: Children transplanted for non-malignant conditions require evidence-based survivorship programs to reduce excess morbidity and mortality.
MeSH term(s)	Adolescent ; Anemia, Aplastic/complications ; Anemia, Aplastic/therapy ; Australia/epidemiology ; Bone Marrow Diseases/complications ; Bone Marrow Diseases/therapy ; Child ; Child, Preschool ; Female ; Follow-Up Studies ; Graft vs Host Disease/epidemiology ; Graft vs Host Disease/etiology ; Graft vs Host Disease/mortality ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hemoglobinuria, Paroxysmal/complications ; Hemoglobinuria, Paroxysmal/therapy ; Humans ; Incidence ; Infant ; Infant, Newborn ; Male ; Metabolism, Inborn Errors/complications ; Metabolism, Inborn Errors/therapy ; Neoplasms/epidemiology ; Neoplasms/etiology ; Neoplasms/mortality ; Prognosis ; Risk Factors ; Survival Rate ; Transplantation, Homologous ; X-Linked Combined Immunodeficiency Diseases/complications ; X-Linked Combined Immunodeficiency Diseases/therapy
Language	English
Publishing date	2017
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2131448-2
ISSN	1545-5017 ; 1545-5009
ISSN (online)	1545-5017
ISSN	1545-5009
DOI	10.1002/pbc.26219
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1131: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito